Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
- Conditions
- Breast Cancer
- Interventions
- Registration Number
- NCT05501886
- Lead Sponsor
- Celcuity Inc
- Brief Summary
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
- Detailed Description
This is a Phase 3, open-label, randomized clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Gedatolisib is an intravenously administered pan-PI3K/mTOR inhibitor. Palbociclib is a CDK4/6 inhibitor. Fulvestrant is a selective estrogen receptor degrader (SERD). Subjects will be assessed for PIK3CA status and then randomized to treatment arms according to their confirmed PIK3CA mutation status.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 701
- Histologically or cytologically confirmed diagnosis of metastatic or locally advanced breast cancer Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with an LHRH agonist. Patients are to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and must be willing to continue on it for the duration of the study.
- Negative pregnancy test for women of childbearing potential. Female subjects of childbearing potential must use an effective and/or acceptable contraceptive method from screening until 1 year after the last dose of study treatment
- Confirmed diagnosis of estrogen receptor positive and/or progesterone receptor positive, as per American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines (2020), based on most recent tumor biopsy utilizing an assay consistent with local standards
- Documented HER2 immunohistochemistry (IHC) negative as per ASCO-CAP 2018 guidance
- Adequate archival or fresh tumor tissue for the analysis of PIK3CA mutational status
- Subject must have documentation of radiological disease progression on or after the last prior treatment and also have radiologically evaluable disease (measurable and/or non-measurable) according to RECIST v1.1, per local assessment. Subjects with bone only disease must have lytic or mixed lytic/blastic lesions that can be accurately assessed; bone only blastic lesions with no soft tissue component is not allowed.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Life expectancy of at least 3 months
- Progressed during or after CDK4/6 inhibitor combination treatment with non-steroidal aromatase inhibitor (AI)
- Adequate bone marrow, hepatic, renal and coagulation function
-
History of malignancies other than adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥3 years
-
Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor, a protein kinase B (Akt) inhibitor, or a mechanistic target of rapamycin (mTOR) inhibitor
-
Prior treatment with chemotherapy and antibody drug conjugates for advanced disease is not permitted (prior adjuvant or neoadjuvant chemotherapy is permitted)
-
More than 2 lines of prior endocrine therapy treatment
-
Bone only disease that is only blastic with no soft tissue component
-
Subjects with type 1 diabetes or uncontrolled type 2 diabetes
-
Known and untreated, or active, brain or leptomeningeal metastases
a. Subjects with previously treated central nervous system (CNS) metastases may be enrolled in the study if they meet the following criteria: do not require supportive therapy with steroids; do not have seizures and do not exhibit uncontrolled neurological symptoms; stable disease confirmed by radiographic assessment within at least 4 weeks prior to enrollment
-
Patients with advanced, symptomatic, visceral spread that are at risk of life-threatening complication in the short-term
-
History of clinically significant cardiovascular abnormalities such as: Congestive heart failure (New York Heart Association (NYHA) classification ≥ II within 6 months of study entry
-
Myocardial infarction within 12 months of study entry
-
History of any uncontrolled (or untreated) clinically significant cardiac arrhythmias, (e.g., ventricular tachycardia), complete left bundle branch block, high grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block), supraventricular, nodal arrhythmias, or conduction abnormality in the previous 12 months
-
Uncontrolled hypertension defined by systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) ≥100 mmHg, with or without antihypertensive medication (initiation or adjustment of antihypertensive medication[s] is allowed prior to screening)
-
Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
- i. Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, or history of clinically significant/symptomatic bradycardia
- ii. On screening, inability to determine the corrected QT interval using Fridericia's formula (QTcF) on the ECG (i.e., unreadable or not interpretable) or QTcF >480 msec (determined by mean of triplicate ECGs at screening)
-
-
Known hypersensitivity to the study drugs or their components
-
Pregnant or breast-feeding women
-
Concurrent participation in another interventional clinical trial
- Subjects must agree not to participate in another clinical trial (other than observational) at any time during participation in VIKTORIA-1.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm C - Patients Lacking PIK3CA Mutations (WT) Fulvestrant Fulvestrant Arm B - Patients Lacking PIK3CA Mutations (WT) Fulvestrant Gedatolisib + Fulvestrant Arm A - Patients Lacking PIK3CA Mutations (WT) Palbociclib Gedatolisib + Palbociclib + Fulvestrant Arm A - Patients Lacking PIK3CA Mutations (WT) Fulvestrant Gedatolisib + Palbociclib + Fulvestrant Arm E - Patients with PIK3CA Mutation (MT) Fulvestrant Alpelisib + Fulvestrant Arm D - Patients with PIK3CA Mutation (MT) Fulvestrant Gedatolisib + Palbociclib + Fulvestrant Arm D - Patients with PIK3CA Mutation (MT) Palbociclib Gedatolisib + Palbociclib + Fulvestrant Arm E - Patients with PIK3CA Mutation (MT) Alpelisib Alpelisib + Fulvestrant Arm F - Patients with PIK3CA Mutation (MT) Fulvestrant Gedatolisib + Fulvestrant Arm A - Patients Lacking PIK3CA Mutations (WT) Gedatolisib Gedatolisib + Palbociclib + Fulvestrant Arm B - Patients Lacking PIK3CA Mutations (WT) Gedatolisib Gedatolisib + Fulvestrant Arm D - Patients with PIK3CA Mutation (MT) Gedatolisib Gedatolisib + Palbociclib + Fulvestrant Arm F - Patients with PIK3CA Mutation (MT) Gedatolisib Gedatolisib + Fulvestrant
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer Approximately 48 months PFS is defined as the time from randomization to death or the first documented progression, whichever occurs first, confirmed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, as determined based on blinded independent central review (BICR)
- Secondary Outcome Measures
Name Time Method Time to Response (TTR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer Up to approximately 48 months Time form randomization to the first assessment of PR or better as assessed by BICR, whichever comes first
Overall Survival (OS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer From date of randomization to the date of death due to any cause, up to approximately 48 months OS is defined as the length of time from randomization until the date of death from any cause method, where PFS is defined as the time from randomization to death or the first documented progression, whichever occurs first, confirmed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, as determined based on blinded independent central review (BICR)
Duration of Response (DOR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer Up to approximately 48 months Time from the assessment of initial response (PR or better) to death or first documented disease progression as assessed by BICR, whichever occurs first
Quality of Life (QOL)Functional Assessment of Cancer Therapy - Breast Trial Outcome Index (FACT-B TOI) Questions in Patients with PIK3CA WT and PIK3CA MT Breast Cancer From baseline to 30 Day Safety Follow-up The FACT-B TOI is an abbreviated (24-item) version of the full FACT-B which focuses only on the patient's Physical Well-being (PWB), Functional Well-being (FWB), and Breast Cancer Subscale (BCS) components using a 5-level scale, (Not at all, A little bit, Some-what, Quite a bit, Very much).
Patient-Reported Outcomes in Patients with PIK3CA WT and PIK3CA MT Breast Cancer From baseline to 30 Day Safety Follow-up Patient-Reported Outcomes Measurement Information System (PROMIS®) Short Form v2.0 - Physical Function 8c using a 5-level scale (Without any difficulty, With a little difficulty, With some difficulty, With much difficulty, Unable to do)
EuroQol 5 in Patients with PIK3CA WT and PIK3CA MT Breast Cancer From baseline to 30 Day Safety Follow-up EuroQol 5 Dimension 5 Level (EQ-5D-5L) - This is a 5 question, self-administered visual analog scale (VAS) where patients use 0 (worst health) to 100 (best health) to indicate how they view their health.
Quality of Life (QOL) NCCN-FACT Breast Symptom Index -16 (NFBSI-16) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer From baseline to 30 Day Safety Follow-up NCCN-FACT is derived from the FACT-B and only 4 additional items will be administered to enable optional scoring of the NFBSI subscales and total score using a 5-level scale (Not at all, A little bit, Some-what, Quite a bit, Very much).
Overall Response Rate (ORR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer Up to approximately 48 months Percentage of subjects who achieved an objective response according to RECIST v1.1 criteria (complete response \[CR\] or partial response \[PR\]) as assessed by BICR)
Clinical Benefit Rate (CBR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer Up to approximately 48 months Percentage of subjects with CR, PR, or stable disease (SD) \>24 weeks as assessed by BICR
Adverse Events Up to approximately 48 months Safety and tolerability will be evaluated by review of type, incidence, severity (as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] v5.0), seriousness, and relationship to study medications of adverse events (AEs) and any laboratory abnormalities
Trial Locations
- Locations (217)
H. Lee Moffitt Cancer Center & Research Institute
🇺🇸Tampa, Florida, United States
Bond & Steele Clinic, P.A. d/b/a Bond Clinic, P.A.
🇺🇸Winter Haven, Florida, United States
John D. Archbold Memorial Hospital
🇺🇸Thomasville, Georgia, United States
Illinois Cancer Specialists - Arlington Heights
🇺🇸Arlington Heights, Illinois, United States
Fort Wayne Medical Oncology and Hematology
🇺🇸Fort Wayne, Indiana, United States
University of Kentucky Medical Center
🇺🇸Lexington, Kentucky, United States
Mercy Health - Paducah
🇺🇸Paducah, Kentucky, United States
American Oncology Partners of Maryland, PA
🇺🇸Bethesda, Maryland, United States
Maryland Oncology Hematology, P.A. - Rockville
🇺🇸Rockville, Maryland, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
Nebraska Hematology - Oncology, P.C.
🇺🇸Lincoln, Nebraska, United States
Oncology Hematology West PC dba Nebraska Cancer Specialists
🇺🇸Omaha, Nebraska, United States
University of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
New York Oncology Hematology, P.C. - Albany
🇺🇸Albany, New York, United States
Severance Hospital, Yonsei University Health System
🇰🇷Soeul, Korea, Republic of
Ulsan University Hospital
🇰🇷Ulsan, Korea, Republic of
Clinical Research Center Chapultepec Mexico City
🇲🇽Mexico City, Mexico
CRYPTEX
🇲🇽Mexico City, Mexico
ProcliniQ Clinical Research
🇲🇽Mexico City, Mexico
Filios High Medicine
🇲🇽Monterrey, Mexico
Administrative Society of Health Services, SC
🇲🇽Morelia, Mexico
Avix Clinical Research
🇲🇽Nuevo León, Mexico
Zambrano Hellion Medical Center
🇲🇽Nuevo León, Mexico
Inbiomedyc
🇲🇽Querétaro, Mexico
ONCOR Life Medical Center
🇲🇽Saltillo, Mexico
Prof. Franciszek Lukaszczyk Oncology Center in Bydgoszcz, Chemotherapy Outpatient Clinic
🇵🇱Bydgoszcz, Poland
Medical Clinic "Komed"
🇵🇱Konin, Poland
Maria Sklodowska-Curie Institute of Oncology, Branch in Krakow
🇵🇱Kraków, Poland
Independent Public Healthcare Facility Prof. Tadeusz Koszarowski Opole Oncology Center in Opole, Clinical Oncology Department and Day Hospitalization Unit
🇵🇱Opole, Poland
St. John Paul 2nd Mazovian Provincial Hospital in Siedlce Limited Liability Company, Siedlce Oncology Centre
🇵🇱Siedlce, Poland
West Pomeranian Oncology Center
🇵🇱Szczecin, Poland
LUX MED Oncology LLC, Szamocka Hospital, Department of Clinical Oncology/Chemotherapy
🇵🇱Warsaw, Poland
Maria Sklodowska-Curie - National Research Institute of Oncology
🇵🇱Warsaw, Poland
Provincial Specialist Hospital in Wroclaw, Department of Chemotherapy
🇵🇱Wroclaw, Poland
Polish Mother's Memorial Hospital-Research Institute
🇵🇱Łódź, Poland
S.C. Oncopremium-Team SRL
🇷🇴Baia Mare, Romania
Prof. Dr. Alexandru Trestioreanu Institute of Oncology
🇷🇴Bucharest, Romania
Prof. Dr. Ion Chiricuta Institute of Oncology
🇷🇴Cluj-Napoca, Romania
Onco Clinic Consult S.A.
🇷🇴Craiova, Romania
Oncology Center "Sf. Nectarie"
🇷🇴Craiova, Romania
S.C. Topmed Medical Center SRL
🇷🇴Târgu-Mureş, Romania
Curie Oncology
🇸🇬Singapore, Singapore
ICON SOC Farrer Park Medical Clinic
🇸🇬Singapore, Singapore
OncoCare Cancer Centre
🇸🇬Singapore, Singapore
Raffles Hospital
🇸🇬Singapore, Singapore
Tan Tock Seng Hospital
🇸🇬Singapore, Singapore
Infanta Cristina Hospital
🇪🇸Badajoz, Spain
Catalan Institute of Oncology, Hospital Duran i Reynals
🇪🇸Barcelona, Spain
Caceres Hospital Complex - San Pedro de Alcantara General Hospital
🇪🇸Cáceres, Spain
Hospital Ruber Internacional
🇪🇸Madrid, Spain
University Hospital Foundation Jimenez Diaz
🇪🇸Madrid, Spain
University Clinical Hospital Virgen de la Arrixaca, Department of Oncology
🇪🇸Murcia, Spain
University Hospital Complex of Santiago (CHUS), Department of Oncology
🇪🇸Santiago De Compostela, Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Taipei Medical University - Shuang Ho Hospital
🇨🇳New Taipei City, Taiwan
China Medical University Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Royal United Hospital, Department of Oncology/Hematology
🇬🇧Bath, United Kingdom
Velindre Cancer Centre
🇬🇧Cardiff, United Kingdom
Guy's Hospital
🇬🇧London, United Kingdom
Royal Marsden Hospital - London, Department of Medical Oncology
🇬🇧London, United Kingdom
The Christie NHS Foundation Trust
🇬🇧Manchester, United Kingdom
Nottingham City Hospital
🇬🇧Nottingham, United Kingdom
St Vincent's Hospital (Melbourne) Ltd
🇦🇺Fitzroy, Australia
Peninsula & South Eastern Hematology and Oncology Group (PSEHOG)
🇦🇺Frankston, Australia
Hollywood Private Hospital, Breast Cancer Research Centre
🇦🇺Nedlands, Australia
Mater Hospital Brisbane, Mater Cancer Care Centre
🇦🇺South Brisbane, Australia
Icon Cancer Centre- Southport
🇦🇺Southport, Australia
Sydney Adventist Hospital
🇦🇺Wahroonga, Australia
The Queen Elizabeth Hospital
🇦🇺Woodville, Australia
University Hospital Graz, Department of Gynecology and Obstetrics
🇦🇹Graz, Austria
University Hospital Innsbruck - Tyrolean Hospital, Department of Gynaecology and Obstetrics
🇦🇹Innsbruck, Austria
Order Hospital Linz Ltd. - Hospital of Sisters of Mercy, Department of Internal Medicine I
🇦🇹Linz, Austria
Salzburg Regional Hospital, Department of Internal Medicine III
🇦🇹Salzburg, Austria
University Hospital St. Poelten, Department of Internal Medicine I
🇦🇹St. Poelten, Austria
Hospital Hietzing, Department of Gynecology
🇦🇹Vienna, Austria
Medical University Vienna, Department of Gynecology and Obstetrics
🇦🇹Vienna, Austria
Saint Luc University Hospital
🇧🇪Brussels, Belgium
Charleroi Grand Hospital (GHDC)
🇧🇪Charleroi, Belgium
University Hospital Antwerp (UZA)
🇧🇪Edegem, Belgium
AZ Groeninge
🇧🇪Kortrijk, Belgium
University Hospitals Leuven, Campus Gasthuisberg
🇧🇪Leuven, Belgium
Citadelle Regional Hospital Center
🇧🇪Liège, Belgium
VITAZ
🇧🇪Sint-Niklaas, Belgium
Centre Hospitalier Peltzer-la-Tourelle
🇧🇪Verviers, Belgium
UCL Mont-Godinne University Hospitals
🇧🇪Yvoir, Belgium
Oncology Treatment Center
🇧🇷Belém, Pará, Brazil
Pronutrir
🇧🇷Fortaleza, Brazil
ONCOSITE - Clinical Research Center in Oncology
🇧🇷Ijuí, Brazil
Juiz de Fora Eurolatino Research Center
🇧🇷Minas Gerais, Brazil
Bahia Oncology Center
🇧🇷Salvador de Bahia, Brazil
D'OR Institute
🇧🇷São Paulo, Brazil
Hospital A.C.Camargo
🇧🇷São Paulo, Brazil
Multiprofile Hospital for Active Treatment - Uni Hospital, Panagyurishte
🇧🇬Panagyurishte, Bulgaria
MHAT for Women's Health "Nadezhda"
🇧🇬Sofia, Bulgaria
Multiprofile Hospital for Active Treatment "Serdika", Sofia
🇧🇬Sofia, Bulgaria
Specialized Hospital for Active Treatment in Oncology, Clinic of Medicial Oncology (Chemotherapy)
🇧🇬Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment "Sveta Marina"
🇧🇬Varna, Bulgaria
BC Cancer - Vancouver, Medical Oncology
🇨🇦Vancouver, British Columbia, Canada
CIUSSS du Saguenay Lac St-Jean
🇨🇦Chicoutimi, Quebec, Canada
Hospital Notre-Dame
🇨🇦Montréal, Quebec, Canada
Maisonneuve-Rosemont Hospital
🇨🇦Montréal, Quebec, Canada
University Hospital Olomouc, Clinic of Oncology
🇨🇿Olomouc, Czechia
Thomayer University Hospital, Clinic of Oncology
🇨🇿Prague, Czechia
University Hospital Bulovka, Institute of Radiation Oncology
🇨🇿Prague, Czechia
University Hospital Motol, Clinic of Oncology
🇨🇿Prague, Czechia
Bergonie Institute
🇫🇷Bordeaux, France
Francois Baclesse Center
🇫🇷Caen, France
La Roche-sur-Yon Hospital
🇫🇷La Roche-sur-Yon, France
CHU La Timone - La Timone Children's Hospital
🇫🇷Marseille, France
University Hospital Center of Poitiers
🇫🇷Poitiers, France
Saint Anne Clinic
🇫🇷Strasbourg, France
Gustave Roussy
🇫🇷Villejuif, France
Hospital Bayreuth
🇩🇪Bayreuth, Germany
Vivantes Hospital Am Urban
🇩🇪Berlin, Germany
Private Practice with Focus on Oncology
🇩🇪Luebeck, Germany
University Hospital Johannes Gutenberg - University of Mainz
🇩🇪Mainz, Germany
Hospital Suedstadt Rostock
🇩🇪Mecklenburg, Germany
University Hospital Muenster
🇩🇪Münster, Germany
Caritas Klinikum
🇩🇪Saarbrücken, Germany
Helios Clinic Wuppertal
🇩🇪Wuppertal, Germany
Alexandra General Hospital
🇬🇷Athens, Greece
University General Hospital of Ioannina
🇬🇷Ioánnina, Greece
IASO Thessaly SA
🇬🇷Larissa, Greece
EUROMEDICA General Clinic of Thessaloniki
🇬🇷Thessaloníki, Greece
Theageneio Anticancer Hospital of Thessaloniki
🇬🇷Thessaloníki, Greece
University of Debrecen Clinical Center, Institute of Oncology
🇭🇺Debrecen, Hungary
Bacs-Kiskun County Hospital, Center for Oncoradiology
🇭🇺Kecskemét, Hungary
Szabolcs-Szatmar-Bereg County Hospitals and University Teaching Hospital, Department of Oncology
🇭🇺Nyíregyháza, Hungary
HCG Cancer Centre
🇮🇳Bangalore, India
Postgraduate Institute of Medical Education and Research (PGIMER)
🇮🇳Chandigarh, India
Tata Medical Center
🇮🇳Kolkata, India
Tata Memorial Hospital
🇮🇳Navi Mumbai, India
Christian Medical College, Department of Medical Oncology
🇮🇳Vellore, India
European Institute of Oncology (IEO), IRCCS
🇮🇹Milan, Italy
University Polyclinic Hospital of Modena
🇮🇹Modena, Italy
Local Healthcare Company of Monza (ASST Monza)
🇮🇹Monza, Italy
University Hospital of Parma
🇮🇹Parma, Italy
New Hospital of Prato (NOP)
🇮🇹Prato, Italy
University Hospital Campus Bio-Medico
🇮🇹Rome, Italy
University Polyclinic Foundation "Agostino Gemelli" - IRCCS
🇮🇹Rome, Italy
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Santa Maria della Misericordia University Hospital of Udine
🇮🇹Udine, Italy
Gangnam Severance Hospital
🇰🇷Soeul, Korea, Republic of
Korea University Anam Hospital
🇰🇷Soeul, Korea, Republic of
Samsung Medical Center
🇰🇷Soeul, Korea, Republic of
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Arizona Oncology (US Oncology/McKesson) - Goodyear
🇺🇸Goodyear, Arizona, United States
St. Bernards Medical Center
🇺🇸Jonesboro, Arkansas, United States
CARTI Cancer Center
🇺🇸Little Rock, Arkansas, United States
Pacific Cancer Medical Center Inc
🇺🇸Anaheim, California, United States
Kaiser Permanente South Bay Medical Center
🇺🇸Harbor City, California, United States
Cancer and Blood Specialty Clinic
🇺🇸Los Alamitos, California, United States
Pacific Cancer Care
🇺🇸Monterey, California, United States
University of California, Irvine Medical Center
🇺🇸Orange, California, United States
Ventura County Hematology Oncology Specialists
🇺🇸Oxnard, California, United States
Redlands Hematology Oncology
🇺🇸Redlands, California, United States
UCLA Hematology/Oncology-Santa Monica
🇺🇸Santa Monica, California, United States
Torrance Memorial Physician Network - Cancer Care
🇺🇸Torrance, California, United States
Kaiser Permanente Medical Center - Vallejo
🇺🇸Vallejo, California, United States
PIH Health Hospital Whittier
🇺🇸Whittier, California, United States
Yale Cancer Center - New Haven
🇺🇸New Haven, Connecticut, United States
South Broward Hospital District d/b/a Memorial Healthcare System
🇺🇸Hollywood, Florida, United States
Cancer Specialists of North Florida - Jacksonville
🇺🇸Jacksonville, Florida, United States
Montefiore Medical Center
🇺🇸Bronx, New York, United States
Queens Hospital Cancer Center
🇺🇸Jamaica, New York, United States
Coleman, Pasmantier & Decter, MDs
🇺🇸New York, New York, United States
Weill Cornell Medicine/New York-Presbyterian Hospital
🇺🇸New York, New York, United States
University of Rochester Medical Center
🇺🇸Rochester, New York, United States
Hematology/Oncology Associates of Central New York
🇺🇸Syracuse, New York, United States
White Plains Hospital
🇺🇸White Plains, New York, United States
Cone Health Cancer Center at Alamance Regional, Hematology/Oncology
🇺🇸Greensboro, North Carolina, United States
Southeast Regional Cancer Center
🇺🇸Lumberton, North Carolina, United States
University Hospitals Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States
The James Cancer Hospital and Solove Research Institute
🇺🇸Columbus, Ohio, United States
OU Health Stephenson Cancer Center
🇺🇸Oklahoma City, Oklahoma, United States
Oregon Oncology Specialists
🇺🇸Salem, Oregon, United States
Northwest Cancer Specialists, PC - Tigard
🇺🇸Tigard, Oregon, United States
Consultants In Medical Oncology and Hematology, P.C.
🇺🇸Broomall, Pennsylvania, United States
Alliance Cancer Specialists PC
🇺🇸Horsham, Pennsylvania, United States
Cancer Care Associates of York
🇺🇸York, Pennsylvania, United States
Sanford Gynecologic Oncology Clinic
🇺🇸Sioux Falls, South Dakota, United States
Texas Oncology - Austin
🇺🇸Austin, Texas, United States
Texas Oncology P.A. - Dallas
🇺🇸Dallas, Texas, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
🇺🇸Dallas, Texas, United States
William Beaumont Army Medical Center
🇺🇸El Paso, Texas, United States
Oncology Consultants
🇺🇸Houston, Texas, United States
Adelaide Oncology & Haematology
🇦🇺Adelaide, Australia
University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Brooke Army Medical Center
🇺🇸Houston, Texas, United States
Texas Oncology - McKinney
🇺🇸McKinney, Texas, United States
Texas Oncology - Gulf Coast
🇺🇸Sugar Land, Texas, United States
Texas Oncology - Tyler
🇺🇸Tyler, Texas, United States
Fort Belvoir Community Hospital
🇺🇸Fort Belvoir, Virginia, United States
Bon Secours St. Francis Medical Oncology Center
🇺🇸Midlothian, Virginia, United States
Virginia Oncology Associates - Newport News
🇺🇸Newport News, Virginia, United States
VCU Massey Cancer Center
🇺🇸Richmond, Virginia, United States
Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care - Roanoke
🇺🇸Roanoke, Virginia, United States
Fred Hutchinson Cancer Center
🇺🇸Seattle, Washington, United States
Northwest Medical Specialties, PLLC - Tacoma
🇺🇸Tacoma, Washington, United States
Alexander Fleming Institute
🇦🇷Buenos Aires, Argentina
Buenos Aires British Hospital
🇦🇷Buenos Aires, Argentina
CENIT Foundation
🇦🇷Buenos Aires, Argentina
Center for Medical Education and Clinical Research (CEMIC)
🇦🇷Buenos Aires, Argentina
Fleischer Medical Center
🇦🇷Buenos Aires, Argentina
Medical Center Austral
🇦🇷Buenos Aires, Argentina
Pergamino Clinic
🇦🇷Buenos Aires, Argentina
Cordoba Oncology Institute (IONC)
🇦🇷Córdoba, Argentina
Center of Nuclear and Molecular Medicine of Entre Rios (CEMENER)
🇦🇷Paraná, Argentina
CEDIT Diagnostic and treatment center
🇦🇷Salta, Argentina
CER San Juan
🇦🇷San Juan, Argentina
Rosario's Oncology Institute and Medical Specialities (IOR)
🇦🇷Santa Fe, Argentina
9 of July Sanatorium
🇦🇷Tucumán, Argentina